These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 26237101)

  • 1. Population-based analysis of HIV-1 antibodies reveals structural constraints that may inform vaccine design.
    Tobin SC
    AIDS; 2015 Sep; 29(15):N13. PubMed ID: 26237101
    [No Abstract]   [Full Text] [Related]  

  • 2. AIDS/HIV. A boost for HIV vaccine design.
    Burton DR; Weiss RA
    Science; 2010 Aug; 329(5993):770-3. PubMed ID: 20705840
    [No Abstract]   [Full Text] [Related]  

  • 3. AIDS/HIV. Converging on an HIV vaccine.
    Korber B; Gnanakaran S
    Science; 2011 Sep; 333(6049):1589-90. PubMed ID: 21921189
    [No Abstract]   [Full Text] [Related]  

  • 4. HIV vaccine design and the neutralizing antibody problem.
    Burton DR; Desrosiers RC; Doms RW; Koff WC; Kwong PD; Moore JP; Nabel GJ; Sodroski J; Wilson IA; Wyatt RT
    Nat Immunol; 2004 Mar; 5(3):233-6. PubMed ID: 14985706
    [No Abstract]   [Full Text] [Related]  

  • 5. The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development.
    O'Connell RJ; Kim JH; Excler JL
    Expert Rev Vaccines; 2014 Dec; 13(12):1489-500. PubMed ID: 25163695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GP120: target for neutralizing HIV-1 antibodies.
    Pantophlet R; Burton DR
    Annu Rev Immunol; 2006; 24():739-69. PubMed ID: 16551265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1MN recombinant gp120 vaccine serum, which fails to neutralize primary isolates of HIV-1, does not antagonize neutralization by antibodies from infected individuals.
    Wrin T; Nunberg JH
    AIDS; 1994 Nov; 8(11):1622-3. PubMed ID: 7848602
    [No Abstract]   [Full Text] [Related]  

  • 8. Virology. HIV may shed some protection as it jumps to new hosts.
    Cohen J
    Science; 2004 Mar; 303(5666):1956. PubMed ID: 15044774
    [No Abstract]   [Full Text] [Related]  

  • 9. AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope.
    Emini EA; Koff WC
    Science; 2004 Jun; 304(5679):1913-4. PubMed ID: 15218131
    [No Abstract]   [Full Text] [Related]  

  • 10. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design.
    Saphire EO; Parren PW; Pantophlet R; Zwick MB; Morris GM; Rudd PM; Dwek RA; Stanfield RL; Burton DR; Wilson IA
    Science; 2001 Aug; 293(5532):1155-9. PubMed ID: 11498595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design.
    Zolla-Pazner S; Cardozo T
    Nat Rev Immunol; 2010 Jul; 10(7):527-35. PubMed ID: 20577269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies to HIV-1: aiming at the right target.
    Eggink D; Melchers M; Sanders RW
    Trends Microbiol; 2007 Jul; 15(7):291-4. PubMed ID: 17566740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antigenic structure of the HIV gp120 envelope glycoprotein.
    Wyatt R; Kwong PD; Desjardins E; Sweet RW; Robinson J; Hendrickson WA; Sodroski JG
    Nature; 1998 Jun; 393(6686):705-11. PubMed ID: 9641684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunologic mechanism for human immunodeficiency virus type 1 gp120 vaccine failure.
    O'Toole C; Müller S; Nara P; Köhler H
    J Infect Dis; 1996 Feb; 173(2):512-3. PubMed ID: 8568327
    [No Abstract]   [Full Text] [Related]  

  • 15. Importance of conformation on the neutralizing antibody response to HIV-1 gp120.
    Steimer KS; Haigwood NL
    Biotechnol Ther; 1991; 2(1-2):63-89. PubMed ID: 1726963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV. Escape artist par excellence.
    Cohen J
    Science; 2003 Mar; 299(5612):1505-8. PubMed ID: 12624245
    [No Abstract]   [Full Text] [Related]  

  • 17. The RV144 Thai HIV vaccine trial.
    Plotkin SA
    Hum Vaccin; 2010 Feb; 6(2):159. PubMed ID: 20431337
    [No Abstract]   [Full Text] [Related]  

  • 18. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission.
    Derdeyn CA; Decker JM; Bibollet-Ruche F; Mokili JL; Muldoon M; Denham SA; Heil ML; Kasolo F; Musonda R; Hahn BH; Shaw GM; Korber BT; Allen S; Hunter E
    Science; 2004 Mar; 303(5666):2019-22. PubMed ID: 15044802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does the key to a successful HIV type 1 vaccine lie among the envelope sequences of infected individuals?
    Rencher SD; Slobod KS; Dawson DH; Lockey TD; Hurwitz JL
    AIDS Res Hum Retroviruses; 1995 Sep; 11(9):1131-3. PubMed ID: 8554911
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunology. Bound for glory.
    Cohen J
    Science; 2013 Sep; 341(6151):1168-71. PubMed ID: 24030996
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.